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Nowadays, the surgical techniques for treating type 2 diabetes (T2DM) include: Ileal Interposition (II), Ileal Interposition
in combination with Sleeve Gastrectomy (IISG) and Diverted Sleeve Gastrectomy (IIDSG). These procedures are not only
for obese subjects, but are also used for non-obese subjects. These types of surgical procedures can improve glycemic
control, and lead to a significant reduction in oral hypoglycemic agents (OHAs) and insulin therapy. The results of
various studies have shown the safety, feasibility, and efficacy of the surgical procedure for the treatment of T2DM.
Although it is an effective treatment option, this procedure is not recommended for general use and long-term studies
are needed to confirm these findings and potential side effects on a larger number of patients.Background
Obesity, type 2 diabetes (T2DM) and metabolic disorders
are the most major health problems with an increasing
prevalence globally. The two latter complications are dir-
ectly related to the obesity, while some other complica-
tions are results of metabolic abnormality associated with
obesity [1, 2].
Diabetes mellitus is a chronic disease and a common
cause of morbidity and mortality around the world. The
global prevalence of diabetes among adults (aged 20–
79 years) in 2010 was 6.4 % (285 million adults) [3].
Also, world Health Organization (WHO) has reported
that by 2030, the prevalence of T2DM will increase to
336 million subjects [4]. Considering the global health
crisis of diabetes and obesity in this era and the need
for an effective treatment of patients, surgery can be
proposed in addition to drug therapy (Synthetic and
Medicinal plants) [5, 6].
In the past, other surgical procedures including sleeve
gastrectomy (SG), gastric banding, Roux-en-Y-Gastric
Bypass (RYGB) and Jejuno-Ileal Bypass (JIB) were used
to treat diabetes. But today, other surgical procedures
have been modified to achieve the maximum remission* Correspondence: Sh_hasani@sina.tums.ac.ir
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stated.in diabetic patients [7, 8]. Now, the surgical techniques for
treating type 2 diabetes include: Ileal Interposition (II), Ileal
Interposition in combination with Sleeve Gastrectomy
(IISG) and Diverted Sleeve Gastrectomy (IIDSG) [7, 9].
These procedures are not limited to remission of T2DM,
beside hypertension, hyperlipidemia, obesity, and obstruct-
ive sleep apnea may also be influenced [10–13].
Main text
Ileal Interposition is not only specifically a bariatric sur-
gery, but also is used to treat diseases that target the
metabolic syndrome such as T2DM. Moreover, both
foregut (excluding of the duodenum) and hindgut mech-
anisms are utilized in these procedures [11, 14, 15].
These procedures not only for obese subjects, but is also
used for non-obese subjects [8, 16–18].
Several studies have shown that these types of surgical
procedures can improve glycemic control, (including re-
ductions in HbA1c, fasting blood glucose (FBG), post-
prandial glucose (PPG)) and also may improve the
metabolic parameters. These results persisted in all pa-
tients during the 3-year follow-up [12, 16–18].
Weight loss by these procedures was attributed to the
increased release of peptides secreted in the ileum, GLP-1
and peptide YY (PYY), which has anorectic effects [19]. In
the ileal interposition procedure, earlier exposure of food
to ileum and rapid stimulation of the interposed ileal
segment by ingested food leads to augmented glucagon-
like peptide 1 (GLP-1) secretion [12, 17]. GLP-1 resulted
in delaying gastric emptying, promotes satiety, suppressingss This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
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e if changes were made. The Creative Commons Public Domain Dedication
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neogenesis, and stimulating the glycogenesis [20, 21].
Ghrelin stimulates the secretion of hyperglycemic hor-
mones such as glucagon, cortisol and growth hormone
and also inhibit insulin secretion. Ghrelin is an orexigenic
hormone (appetite stimulant). In the SG component of
the IISG and IIDSG procedures, serum level of ghrelin is
reduced and patients feel satiety and restrict their caloric
intake [22–24].
Ileal Interposition is a procedure that does not lead
to malabsorption. In IIDSG procedure, duodenum and
part of the jejunum are bypassed and can cause malab-
sorption. All patients are recommended to take iron,
calcium, B12, and multivitamins supplementation regu-
larly [12, 25].
De paula et al. in their study have reported objective im-
provement of retinopathy and symptomatic improvement
in neuropathy [18]. Also, other studies have reported that
after the metabolic surgery, a significant reduction in oral
hypoglycemic agents (OHAs) and insulin therapy was ob-
served for glycemic control [11, 17, 18].
Usually, patients with shorter duration of diabetes,
higher BMI (Body Mass Index) and higher C-peptide level
respond better to these surgical procedures [11, 26, 27].
In some studies minor and early postoperative compli-
cations such as vomiting, esophagitis, bowel obstruction,
gout, and urinary tract infection have been observed.
But so far, no major long-term surgical complications
have been reported [18, 23]. In advanced T2DM, iatro-
genic hypoglycemia can be a limiting factor for these
procedures [28].
In a study published recently, Ugale et al. introduced a
novel tool known as Diabetes Remission Score (DRS) for
choosing the type of surgery and predicting diabetes
remission following IISG or IIDSG. The study aimed at
presenting an effective and useful method based on pa-
rameters such as the duration of diabetes, BMI and
stimulated C-peptide response prior to surgery for pre-
dicting post surgery diabetes remission [8]. The DRS in-
cluded three grades as grade 1 (mild, DRS 7–8), grade 2
(moderate, 9–11) and grade 3 (severe, DRS 12–14).
Higher scores could be associated with lower chance of
remission.
In conclusion, the results of various studies have
shown the safety, feasibility, and efficacy of the surgical
procedure for the treatment of T2DM. Although it is an
effective treatment option, this procedure is not recom-
mended for general use and long-term studies are
needed to confirm these findings and potential side ef-
fects on a larger number of patients.Abbreviations
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